Document:

Amendment No.1 to Collaboration Agreement dated July 28, 2003

 Exhibit 10.1 
  
 AMENDMENT NO. 1 TO 
 COLLABORATION AGREEMENT 
  
 THIS AMENDMENT NO. 1
to Collaboration Agreement (this “Amendment”), effective as of July 28, 2003 (the “Amendment Date”), is entered into by and between Genencor International, Inc., a Delaware corporation having its principal place of
business at 925 Page Mill Road, Palo Alto, CA 94304-1013 (“GCOR”), and Seattle Genetics, Inc., a Delaware corporation having its principal place of business at 21823 30th Drive S.E. Bothell, WA 98021 (“SGI”). 
  
 RECITALS 
  
 WHEREAS, GCOR and SGI entered into that certain Collaboration Agreement dated as of January 4, 2002 (the “Agreement”) and,
pursuant to the Agreement, have conducted research activities regarding SGI’s ADEPT platform and lead ADEPT molecule, SGN-17/19, and GCOR’s TEPT and i-mune technologies. 
  
 WHEREAS, the parties now wish to amend the Agreement to, among other things, (a) provide for an extension of the term
of the Agreement in consideration for a payment by GCOR of an extension fee, (b) allow each party to develop and commercialize Products in the Field independently from the Collaboration, (c) following termination or expiration of the Agreement,
allow each Party to develop and commercialize on its own any non-Collaboration Products that were originated by such Party during the term of the Agreement and (d) provide that SGN-17/19 shall no longer be a Collaboration Product. 
  
 NOW THEREFORE, in consideration of the foregoing premises and the mutual
covenants set forth below, the parties amend the Agreement and otherwise agree as follows: 
  
 1. Definitions and Cross References. Unless specified herein, each capitalized term shall have the meaning assigned to it in the Agreement and each reference to a Section or Article shall refer to the
corresponding Section or Article in the Agreement. 
  
 1.1 The
following definitions shall replace and or supplement the current definitions in Section 1 of the Agreement: 
  
 “[***]” means the [***], as amended on [***] and [***]. 
  
 “Collaboration” means all research, development, manufacture
and commercialization activities conducted by or on behalf of the Parties relating specifically to a Collaboration Product according to the terms of this Agreement. 
  
 “Collaboration Product” means any Product that the parties mutually agree in writing to co-develop pursuant
to this Agreement. 
  
 [***] Confidential treatment requested. 

 “Cost of Goods” means with respect to material supplied by one Party to the other
hereunder: (i) if manufactured by a Third Party for the supplying Party, the supplying Party’s [***]; and (ii) if manufactured by the supplying Party or its Affiliates, [***]. 
  
 “Development Decision” with respect to a Product means the
earlier of (a) initiation of an [***] for such Product or (b) the [***] for such Product. 
  
 “Development Program” means any activities conducted by or on behalf of the Parties with respect to a Collaboration Product pursuant to a
Development Decision. 
  
 “Effective Date” means
January 4, 2002. 
  
 “Extension Fee” has the
meaning set forth in Section 4.2(e) of the Agreement. 
  
 “FTE Fees” has the meaning set forth in Section 7.6 of the Agreement. 
  
 “GCOR Background Know-How” means all Information and Inventions in the Control of GCOR as of the Effective Date or at any time during the
Term that [***] are deemed necessary or reasonably useful for the Collaboration or for the exercise of the GCOR Background Patents, including without limitation all Information and Inventions relating to [***], but excluding: (a) any
[***]; and (b) any [***]. 
  
 “GCOR
Background Patents” means: (a) all Patents listed in Exhibit E to the Agreement; and (b) any other Patents in the Control of GCOR during the Term that are necessary or reasonably useful for the Collaboration or for the practice of
the GCOR Background Know-How, but excluding: (a) any [***]; (b) any [***]; (c) any [***] and (d) any [***]. 
  
 “GCOR Patents” means GCOR Background Patents, GCOR TEPT Patents and GCOR i-mune Patents. 
  
 “GCOR i-mune Inventions” means any
Information and Inventions made prior to or during the Term solely by SGI employees, solely by GCOR employees or jointly by SGI employees and GCOR employees that relate to the use of or compositions of matter arising from use of i-mune.

  
 “GCOR i-mune Patents”
means any Patents that cover GCOR i-mune Inventions. 
  
 “GCOR i-mune Technology” means GCOR i-mune Patents and GCOR i-mune Inventions. 
  
 “GCOR TE Patents” means (a) all Patents listed in Exhibit D to this Agreement; and (b) any other Patents in the Control of GCOR at any
time during the Term that relate to TE. 
  
 [***]
Confidential treatment requested. 
  

 -2- 

 “GCOR Technology” means GCOR Background Technology, GCOR TEPT Technology and GCOR
i-mune Technology 
  
 “Generic Product”
shall mean, on a country-by-country basis, a Product: (i) the manufacture, use or sale of which is not covered by a Valid Claim in such country, and (ii) that is also marketed by an unlicensed Third Party or Parties in such country, which Third
Party or Parties have, in the aggregate, at least [***]% of the [***] of sales of such Product in any Calendar Quarter in such country, as measured by [***]. 
  
 “i-mune” means methods useful or necessary for determining and engineering T-cell epitope(s) in a
protein, peptide, antibody or fragment of any of these. 
  
 “[***] Product” has the meaning set forth in Section 7.6 of the Agreement. 
  
 “Information and Inventions” means all confidential or proprietary technical, scientific and other know-how and information, trade
secrets, knowledge, technology, means, methods, processes, practices, formulas, instructions, skills, techniques, procedures, experiences, ideas, technical assistance, designs, drawings, assembly procedures, computer programs, apparatuses,
specifications, data, results and other material, including high-throughput screening, gene expression, genomics, proteomics and other drug discovery and development technology, pre-clinical and clinical trial results, manufacturing procedures, test
procedures and purification and isolation techniques, (whether or not patented or patentable) in written, electronic or any other form known as of the Effective Date or developed during the Term. 
  
 “Joint Inventions” means any patentable Information and
Inventions made jointly by SGI employees and GCOR employees, excluding GCOR i-mune Inventions and SGI Prodrug Inventions. 
  
 “Joint Patents” means any Patents (excluding the GCOR i-mune Patents and the SGI Prodrug Patents) jointly owned by the Parties
that relate to Joint Inventions and cover the manufacture, use or sale of Products. 
  
 “Joint Technology” means Joint Patents and Joint Inventions, but excluding SGI Technology and GCOR Technology. 
  

“Major Country” means any of [***]. 
  
 “Product” means any targeted enzyme plus prodrug combination product(s) developed under this Agreement that incorporates Information or
Inventions of a Party or is covered by a Valid Claim of a GCOR Patent, SGI Patent or Joint Patent. 
  
 “Product Trademarks” means the Trademarks developed for Collaboration Products by the Steering Committee and owned jointly by the
Parties, all packaging designs and other trade dress used in connection with the Collaboration Products and such other Trademarks relating thereto and any registrations thereof or any pending applications relating thereto. 
  
 [***] Confidential treatment requested. 
  

 -3- 

 “Research Program” means any research program conducted jointly by the Parties but
funded individually by each Party. 
  
 “Royalty
Term” means, on a Product-by-Product and country-by-country basis, the period of time equal to the longer of: (a) [***] from the date of First Commercial Sale of the Product in such country; or (b) the expiration of the last to
expire of the Valid Claims necessary for the manufacture, use or sale of a Product in such country. 
  
 “SGI Background Know-How” means all Information and Inventions in the Control of SGI as of the Effective Date or at any time during the
Term that at the discretion of SGI are deemed necessary or reasonably useful for the Collaboration or for the exercise of the SGI Background Patents, but excluding any [***] and any [***]. 
  
 “SGI Patents” means SGI Background Patents, SGI ADEPT
Patents, SGI Non-Exclusive Patents and SGI Prodrug Patents. 
  
 “SGI Prodrug Inventions” means any Information and Inventions made prior to or during the Term solely by SGI employees, solely by GCOR employees or jointly by SGI employees and GCOR employees that relate to the use of or
composition of matter of prodrugs activated by beta-lactamase. 
  
 “SGI Prodrug Patents” means any Patents that cover SGI Prodrug Inventions. 
  
 “SGI Prodrug Technology” means any SGI Prodrug Patents and SGI Prodrug Inventions. 
  
 “SGI Technology” means SGI Background Technology, SGI ADEPT
Technology and SGI Prodrug Technology. 
  
 “Stock Purchase
Agreement” means the Common Stock Purchase Agreement effective January 4, 2002 by and between SGI and GCOR attached to the Agreement as Exhibit G. 
  
 “Term” means the period set forth in Section 15.1. 
  
 “Valid Claim” means a claim of an issued and unexpired
patent included in SGI Patents, GCOR Patents or Joint Patents which has not been held permanently revoked, unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within
the time allowed for appeal, and which has not been admitted to be invalid or unenforceable through reissue or disclaimer or otherwise. 
  
 “Work Plan” means the plan developed by the Parties and attached to this Amendment setting forth the Prodrug chemistry to be performed at
SGI during the Term, as may be amended from time-to-time by mutual agreement. 
  
 [***] Confidential treatment requested. 
  

 -4- 

 1.2 The following definitions shall be deleted in their entireties: 
  
 “Improvement” 
  
 “Valid Patent Claim” 
  
 “Renewal Term” 
  
 “Research Costs” 
  
 2. Amendments. 
  
 2.1 Section 2 of the Agreement shall be amended as follows: 
  
 (a) Section 2.1 shall be amended to read in its entirety as follows:

  
 “2.1 Formation of Steering Committee.
Within ten (10) days of a Development Decision or the Parties mutual agreement to conduct a Research Program pursuant to Section 3.2, the Parties shall establish a joint committee (the “Steering Committee”) to make certain
decisions regarding the research or development of Collaboration Products. The Steering Committee will be composed of [***] representatives of each Party, who shall be appointed (and may be replaced at any time) by such Party on written
notice to the other in accordance with this Agreement. Such representatives shall possess the requisite experience and seniority to enable them to make decisions on behalf of the Parties with respect to the Collaboration. Development Decisions, and
such other decisions as expressly set forth herein, shall be subject to approval of the Parties.” 
  
 (b) Section 2.2 of the Agreement shall be amended to read in its entirety as follows: 
  
 “2.2 Responsibilities of the Steering Committee. The Steering Committee will be responsible for, among
other things: 
  
 (a) determining the overall strategy for the
research or development of Collaboration Products in the manner contemplated by this Agreement; 
  
 (b) preparing a Project Plan and Project Budget for each Collaboration Product; 
  
 (c) coordinating, expediting, overseeing and controlling all development of Collaboration Products in the Field, including
pre-clinical research, clinical research, manufacturing, regulatory filings and post approval development studies; 
  
 (d) monitoring, reviewing and directing the commercialization of Collaboration Products within the Field, including developing annual marketing and sales
budgets, annual forecasts or sales and 
  
 [***]
Confidential treatment requested. 
  

 -5- 

 production requirements, an annual marketing plan, product positioning, creative campaign strategies,
pricing and managed care contract strategies; 
  
 (e) evaluating
additional technologies that may be necessary or beneficial for Exploitation of Collaboration Products and recommending the acquisition or in-licensing of these technologies; 
  
 (f) addressing, financial issues which arise in connection with the Collaboration Products in the areas of accounting, cost
allocation, budgeting and financial reporting 
  
 (g) settling
disputes or disagreements between the Parties regarding the Collaboration ; and 
  
 (h) performing such other functions as appropriate to further the purposes of this Agreement.” 
  
 (c) The reference to “Collaboration” in the first sentence of Section 2.3 of the Agreement shall be replaced with a reference to
“Collaboration Products”. 
  
 (d) Section 2.4 shall be
amended to delete all references to “Work Plan”. 
  
 (e) The first sentence of Section 2.5 shall be amended to read in its entirety as follows: “Any dispute that may arise relating to the development or Exploitation of a Collaboration Product or the activities of the Parties hereunder
shall be brought to the attention of the Steering Committee, which shall attempt in good faith to achieve a resolution.” 
  
 2.2 Article 3 of the Agreement shall be modified as follows: 
  
 (a) Section 3.1 shall be deleted in its entirety. 
  
 (b) Section 3.2 shall be amended to read in its entirety as follows: 
  
 “3.2 Scope of the Research Program. As of the Amendment Date, the Parties agree that [***] and
that [***]. Upon mutual written agreement of the Parties, a Research Program may be initiated or reinitiated with respect to a particular Collaboration Product or to cover research efforts relating to SGI Technology and/or GCOR Technology.
Nothing contained in this Agreement shall obligate either SGI or GCOR to provide to the other or to the Collaboration novel cancer targets regardless of whether they might be useful within the Field.” 
  
 [***] Confidential treatment requested. 
  

 -6- 

 (c) Section 3.3 shall be amended to read in its entirety as follows: 
  
 “3.3 Conduct of the Research Program. If the Parties
mutually agree to initiate or reinitiate a Research Program, the Parties shall use Commercially Reasonable Efforts to conduct their respective research and development activities in accordance with this Agreement under the direction and supervision
of the Steering Committee and, in such case, all research work performed by GCOR and SGI pursuant hereto shall be performed in a good scientific manner and in compliance with all applicable laws.” 
  
 (d) Section 3.4 shall be amended to read in its entirety as follows:

  
 “3.4 Research Program Expenses. [***]
costs incurred with respect to any activities undertaken pursuant to a Research Program or its own independent research.” 
  
 (e) The first sentence of Section 3.5 shall be amended to read in its entirety as follows: “The Parties shall determine whether to advance a
Collaboration Product to a Development Program.” 
  
 (f)
Section 3.5(c) shall be amended to read in its entirety as follows: 
  
 “(c) Removal of SGN-17/19 from Collaboration. Effective upon the Amendment Date, the Parties agree that: (a) SGN-17/19 shall no longer be a Collaboration Product, but shall instead be an Independent Product originated and owned
solely by SGI; and (b) unless the Parties mutually agree to make SGN-17/19 a Collaboration Product again, GCOR shall have no further rights under the [***].” 
  
 2.3 Section 4.1 shall be amended to read in its entirety as follows: 
  
 “4.1 Equity Purchase. GCOR has purchased Three Million
U.S. Dollars ($3,000,000) of common stock of SGI on the terms set forth in the Stock Purchase Agreement.” 
  
 2.4 Section 4.2 of the Agreement shall be amended as follows: 
  
 (a) The first sentence of Section 4.2(a) shall be revised to read as follows: “SGI will make a payment of U.S. $[***] to GCOR if [***]
an [***] for a [***] that [***] either:” 
  
 (b) Sections 4.2(b) and 4.2(c) shall be deleted. 
  
 [***] Confidential treatment requested. 
  

 -7- 

 (c) Section 4.2(d) shall be revised to read in its entirety as follows: “GCOR has paid U.S.
$[***] to SGI on the [***] anniversary of the Effective Date.” 
  
 (d) Section 4.2(e) shall be revised to read in its entirety as follows: “GCOR shall make a non-refundable payment of U.S. $[***] to SGI on or before [***] (the “Extension
Fee”).” 
  
 2.5 Section 4.3 of the Agreement shall
be amended as follows: 
  
 (a) The Table in Section 4.3.1 shall
be amended in its entirety as follows: 
  

	 For [***] Products Incorporating:

	  	Rate 1

	 	 	Rate 2

	 
	 [***]
	  	[***	]%	 	[***	]%
			
	 [***]
	  	[***	]%	 	[***	]%
			
	 [***]
	  	[***	]%	 	[***	]%

  
 (b) The Table in
Section 4.3.2 shall be amended in its entirety as follows: 
  

	 For [***] Products Incorporating:

	  	Rate
1

	 	 	Rate
2

	 
	 [***] and/or
	  	 	 	 	 	 
	 [***]
	  	[***	]%	 	[***	]%

  
 A new Section 4.3.3
shall be added to read in its entirety as follows: 
  
 “4.3.3 Ongoing SGN-17/19 Financial Terms. After the Amendment Date, SGI shall not owe GCOR any fees, milestones or royalties regarding SGN-17/19 or any Analogs thereof [***].” 
  
 2.6 Each reference to “[***] Products” in Sections 4.5 and
5.4.1 shall be amended to be a reference to “[***] Products, Independent Products and Post-Termination Products.” 
  
 2.7 A new Section 4.6 shall be added to the Agreement to read in its entirety as follows: 
  
 “4.6 Fees, Milestones, Royalties and Third-Party Obligations For Independent Products and Post-Termination
Products. To obtain and maintain the licenses set forth in Section 15.6.3(c), each Party shall have the obligations set forth in this Section 4.6 with respect to Independent Products and Post-Termination Products that such Party Exploits;
provided that SGN-17/19 shall not be subject to this Section 4.6, but shall instead be subject to Sections 4.2(a) and 4.3.3 of the Agreement. 
  
 [***] Confidential treatment requested. 
  

 -8- 

 4.6.1 License and Milestone Payments. In order to obtain or maintain the licenses granted
pursuant to Section 15.6.3(c), the Party Exploiting an Independent Product or Post-Termination Product shall have the obligation to pay the other Party the following: 
  
 (a) a license fee of [***] for each Independent Product or Post-Termination Product on the earlier of (i) a
[***] with respect to such Independent Product or Post-Termination Product or (ii) [***] after [***]; 
  
 (b) a milestone payment of [***] upon the [***] for each Independent Product or Post-Termination Product; 
  
 (c) a milestone payment of [***] upon the [***] each
Independent Product or Post-Termination Product; 
  
 (d) a
milestone payment of [***] upon the [***] each Independent Product or Post-Termination Product; 
  
 (e) a milestone payment of [***] upon the [***] for each Independent Product or Post-Termination Product; 
  
 (f) beginning on [***] and ending upon the date of [***] of
the Independent Product or Post-Termination Product, the obligation to pay the other Party an annual maintenance fee of [***] per Independent Product or Post-Termination Product that such Party wishes to continue to have the license to
Exploit pursuant to Section 15.6.3(c)[***]. 
  
 4.6.2
Royalties. 
  
 (a) During the
Royalty Term, SGI shall pay GCOR a [***] royalty on Net Sales of any Independent Product or Post-Termination Product (i) that [***] and/or (ii) the [***]. 
  
 (b) During the Royalty Term, GCOR shall pay SGI a [***] royalty on Net Sales of any Independent
Product or Post-Termination Product (i) that [***] and/or (ii) the [***]. 
  
 (c) [***] 
  
 4.6.3 Third-Party Obligations. The Party Exploiting an Independent Product or Post-Termination Product shall be responsible for payment of
[***] arising after the Amendment Date. In addition, GCOR shall pay to SGI an amount equal to [***] of all Third Party Royalties owed to [***] under the [***] on account of GCOR’s Exploitation of Independent Products
or Post-Termination Products. 
  
 [***]
Confidential treatment requested. 
  

 -9- 

 4.6.4 Reduction in Payments and Royalties. If an Independent Product or Post-Termination
Product Exploited by one Party triggers royalty payments pursuant to Section 4.6.2, but the only Valid Claims covering such Independent Product or Post-Termination Product are one or more Joint Patents, then [***] shall thereafter be payable
at [***] of the amounts and rates set forth above for such Independent Product or Post-Termination Product.” 
  
 2.8 Section 6.1 of the Agreement shall be amended to read as follows:  
  
 “6.1 Licenses. 
  

6.1.1 License Grant by SGI. Subject to the terms and conditions of this Agreement, SGI hereby grants to GCOR and its
Affiliates a worldwide, non-exclusive license or sub-license under the SGI Technology and SGI’s interest in Joint Technology, with the limited right to sublicense as permitted in Section 6.4, solely to Exploit Collaboration Products and
[***] Products within the Field. 
  
 6.1.2
License Grant by GCOR. Subject to the terms and conditions of this Agreement, GCOR hereby grants to SGI and its Affiliates a worldwide, non-exclusive license under the GCOR Technology and GCOR’s interest in Joint Technology, with
the limited right to sublicense as permitted in Section 6.4, solely to Exploit Collaboration Products and [***] Products within the Field. 
  
 6.1.3 Financials. The licenses granted in Sections 6.1.1 and 6.1.2 for Collaboration Products shall be royalty free for so
long as it remains a Collaboration Product. The licenses granted in Sections 6.1.1 and 6.1.2 for [***] Products shall be subject to the royalties set forth in Section 4.3.” 
  
 2.9 Section 6.2 of the Agreement shall be deleted in its entirety.

  
 2.10 Section 6.3 of the Agreement shall be amended to read in
its entirety as follows: 
  
 “6.3 Exclusivity of [***]
Product Licenses. If one Party [***] with respect to a particular [***] Product pursuant to Article 7, the [***] Party shall thereupon be automatically deemed to have granted to the [***] Party a [***] to
the extent [***]), license under such Party’s Patents, with the right to sublicense, to Exploit the particular [***] Product within the Field.” 
  
 [***] Confidential treatment requested. 
  

 -10- 

 2.11 Section 6.4 of the Agreement shall be amended to read in its entirety as follows: 
  
 “6.4 Rights to Sublicense. Neither Party may further
sublicense the rights granted to it pursuant to Sections 6.1 or 15.6.3(c) except as follows: (a) the [***] Party may sublicense the rights granted to it pursuant to Section 6.1 to a Sublicensee solely to Exploit a [***] Product in the
Field; (b) a Party originating an Independent Product or Post-Termination Product may sublicense the rights granted to it pursuant to Section 15.6.3(c) to a Sublicensee solely to Exploit such Independent Product or Post-Termination Product
[***]; and (c) each Party may sublicense to a Third Party under its interest in Joint Patents solely for the Exploitation of Products [***]. Neither Party may sublicense or otherwise grant any rights under Joint Patents to any Third
Party [***] except by mutual agreement of the Parties. All such sublicenses granted hereunder by GCOR shall be subject to Section 6.6 to the extent applicable. For all sublicenses under this Section 6.4, the Party granting such sublicense
shall forward to the other Party a fully executed copy of such sublicense agreement or amendment thereof (either of which may be redacted to remove confidential information) within thirty (30) days of execution of such sublicense agreement or
amendment.” 
  
 2.12 Section 6.5 of the Agreement
shall be amended to read in its entirety as follows: 
  
 “6.5 GCOR TEPT Patents and GCOR Background Patents. For purposes of clarification, as of the Amendment Date, SGI shall have no further rights or license under the Agreement to the GCOR TEPT Patents or the GCOR Background
Patents, except with respect to Collaboration Products or [***] Products as provided in Section 6.1.” 
  
 2.13 Section 7.4 of the Agreement shall be amended to read in its entirety as follows: 
  
 “7.4 Third-Party Research, Development and Commercialization of Collaboration Products. The Parties may
upon mutual agreement, license to Third Parties rights with respect to the research, development, manufacture or commercialization of any Collaboration Product or [***] Product on such terms and conditions as the Parties may mutually agree;
provided that any disputes between the Parties as to whether or not to grant such a license shall not be subject to any Third Party dispute resolution mechanism.” 
  
 2.14 The reference in Section 7.5 of the Agreement to “Section 7.3” shall be revised to be
“Section 7.4”. 
  
 2.15 A new Section
7.6 shall be added to the Agreement to read in its entirety as follows: 
  
 [***] Confidential treatment requested. 
  

 -11- 

 “7.6 Independent Products. Subject to payment of the fees, milestone payments and
royalties set forth in Section 4.6, each Party is free to develop and commercialize products incorporating the other Party’s Technology independent from the Collaboration under the licenses granted in Section 15.6.3(c) and, in the absence of a
mutual written agreement of the Parties to designate such Product as a Collaboration Product, such Product shall be deemed an “Independent Product” under this Agreement. Both during the Term and after expiration or termination of
the Agreement, each party shall have the licenses in Section 15.6.3(c) with respect to Exploitation of Independent Products. All expenses associated with Independent Products shall be the [***]. During the Term, each Party may request that
the other Party provide assistance regarding Independent Products, and the other Party will use reasonable commercial efforts to provide such assistance up to a maximum of [***] FTEs. Any FTE funding will be for a minimum of [***]
continuous months and subject to [***] months notice for binding projections. Neither Party shall be obligated to provide any assistance beyond [***] FTEs, which shall be rendered, if at all, in such Party’s sole discretion.
Each Party shall compensate the other Party at an annual rate of [***] per FTE for assistance rendered prior to [***] (the “FTE Fees”). Commencing [***] and every [***] anniversary thereafter, the annual
rate for the FTE Fees will increase by [***] per FTE. Each Party shall also pay the other Party for all reagents and materials requested to be supplied by one Party to the other Party hereunder at a price equal to the supplying Party’s
Cost of Goods plus mark up set forth in the Work Plan (the “Supply Fees”). The FTE Fees and the Supply Fees are collectively referred to herein as the “Research Fees”. Within thirty (30) days after the end of each
Calendar Quarter, each party shall submit a report to the other Party supporting the calculation of the Research Fees due for such Calendar Quarter. Each party shall pay all Research Fees owed to the other Party within thirty (30) days of receipt of
each report. For purposes of clarification, Products other than [***] that are developed as Collaboration Products (either initially or upon conversion pursuant to Section 7.7), but for which a party subsequently [***] pursuant to
Section 7.1, shall be deemed [***] Products rather than Independent Products under this Agreement.” 
  
 2.16 A new Section 7.7 shall be added to the Agreement to read in its entirety as follows: 
  
 “7.7 Conversion of an Independent Product to a Collaboration Product. At any time during the Term, the
Party that originated an Independent Product may, in its sole discretion, elect to offer such Independent Product to the other Party as a Collaboration Product. The non-originating Party may, in its sole discretion, determine whether or not to
accept such Independent Product as a Collaboration Product. If both Parties agree to convert an Independent Product to a Collaboration Product, then the Parties shall negotiate in good faith the terms for such conversion, including without
limitation fees, milestone payments, royalties and co-funding arrangements.” 
  
 [***] Confidential treatment requested. 
  

 -12- 

 2.17 Section 8.1 of the Agreement shall be amended to read in its entirety as follows: 
  
 “8.1 Exchange of Know-How. During the Term, each Party
will, and will cause its Affiliates and Sublicensees, as applicable, to, without additional compensation and at such Party’s sole expense, disclose and make available to the other Party, in whatever form each such other Party may reasonably
request, all Regulatory Documentation, all of its Background Know-How and any other Information and Inventions reasonably necessary for the Exploitation of any Collaboration Product.” 
  
 2.18 The first sentence of Section 9.5 shall be amended to read as follows:

  
 “Neither Party may publish, present or announce any
Confidential Information of the other Party or any results of research or development activities hereunder that relate to the other Party’s technology, either orally or in writing (the “Publication”), without obtaining the written
consent of the other Party.” 
  
 2.19 Section 11.1 shall be
amended to read in its entirety as follows: 
  
 “11.1
Intellectual Property Ownership. SGI shall own all right, title and interest in all SGI Technology (including without limitation all SGI Prodrug Inventions and SGI Prodrug Patents). GCOR shall own all right, title and interest in all
GCOR Technology (including without limitation all GCOR i-mune Inventions and GCOR i-mune Patents). Each Party shall retain [***] in any Joint Patents, with [***] rights in any field and subject to the licenses and right
to sublicense granted in Article 6 and Section 15.6.3(c). The laws of the United States with respect to joint inventorship shall apply in all jurisdictions giving force and effect to this Agreement. This Section 11.1 shall have retroactive
application back to the Effective Date of the Agreement.” 
  
 2.20 The final sentence of Section 11.2 shall be amended to read as follows: 
  
 “The Parties shall each own [***] in each Product Trademark with respect to a Collaboration Product. In the event that a Party [***] with respect to a Collaboration Product, it shall, without any
additional consideration, assign all of its right, title and interest in and to any Product Trademark with respect to such [***] Product to the [***]; provided, however, that each Party shall retain all of its right,
title and interest in and to any Product Trademarks with respect to its own [***] Products.” 
  
 [***] Confidential treatment requested. 
  

 -13- 

 2.21 Section 11.3 shall be amended to read in its entirety as follows: 
  
 “11.3 Ownership of Regulatory Documentation. The Parties
shall jointly own all Regulatory Documentation with respect to Collaboration Products. SGI shall own all Regulatory Documentation with respect to SGN-17/19. Each Party shall own all right, title and interest in and to all Regulatory Documentation
with respect to any Independent Products or Post-Termination Products such Party originated. Each Continuing Party shall have the right to own all right, title and interest in and to all Regulatory Documentation with respect to its [***]
Products. In the event that a Party [***] with respect to a Collaboration Product in a Development Program, it shall assign all of its right, title and interest in and to all Regulatory Documentation with respect to such [***] Product,
including any Regulatory Approvals and applications therefore, to the Continuing Party (or its designee); provided, however, that each Party shall retain any of its right, title and interest in and to any Regulatory Documentation with
respect to a [***] Product. Notwithstanding the ownership of any Regulatory Approval or any other Regulatory Documentation, each Party shall have the right to use and reference any of the Regulatory Documentation in connection with the
Exploitation of any Products as provided in this Agreement.” 
  
 2.22 The first sentence of Section 12.4 shall be amended to read as follows: “The Steering Committee, with respect to a Collaboration Product, shall supervise and direct the filing, prosecution and maintenance of the registrations of
the Product Trademarks for such Product. 
  
 2.23 All references
in Sections 12.7, 13.1 and 13.1.1 shall be replaced with references to “Joint Patents”. 
  
 2.24 Section 15.1 of the Agreement shall be amended to read in its entirety as follows: 
  
 “15.1 Term. The term of this Agreement shall commence on the Effective Date and shall continue in effect
until [***] (the “Term”), unless terminated at an earlier date in accordance with the terms and conditions set forth in this Article 15.” 
  
 2.25 The first sentence of Section 15.6.1 shall be amended to read as follows: “Upon expiration or termination of the
Agreement, the Parties shall discontinue any ongoing Research Program with respect to all Products that have not yet entered a Development Program.” 
  
 2.26 Sections 15.6.3(a) and 15.6.3(b) shall be deleted in their entireties. 
  
 2.27 Section 15.6.3(c) shall be amended to read in its entirety as follows: 
  
 [***] Confidential treatment requested. 
  

 -14- 

 “(c) Independent and Post-Termination Products. During the Term with respect to Independent
Products and after termination or expiration of this Agreement with respect to Independent Products and Post-Termination Products, the Parties hereby agree: 
  
 (i) [***] To SGI. Subject to Section 15.6.3(c)(iv) and other applicable terms and conditions of this Agreement, GCOR
shall [***]: (1) up to [***] Independent Products that SGI originated during the Term and (2) any Collaboration Products that SGI originated that were not in a Development Program on the date of termination or expiration of the Term
(“SGI Post-Termination Products”). 
  
 (ii) [***] To GCOR. Subject to Section 15.6.3(c)(iv) and other applicable terms and conditions of this Agreement SGI shall [***]: (1) up to [***] Independent Products that GCOR originated during the Term
and (2) any Collaboration Products that GCOR originated that were not in a Development Program on the date of termination or expiration of the Term (“GCOR Post-Termination Products” and together with SGI Post-Termination Products,
“Post-Termination Products”); provided that to the extent such Independent Product or GCOR Post-Termination Product incorporates or uses technology covered by the SGI [***] Patents or any Know-How licensed to SGI under the
[***] (as used in paragraph, “Know-How” shall have the meaning set forth in the [***]), in which case this license shall be limited to the [***]. 
  
 (iii) [***]. Each Party agrees to provide the other Party a fully executed copy of any permitted
[***] agreement or amendment thereof entered into pursuant to this Section 15.6.3(c) (either of which may be redacted to remove confidential information) within thirty (30) days of execution of such agreement or amendment.” 

 
 (iv) Payment Obligations. The [***] set
forth in Section 15.6.3(c) shall be subject to payment of the obligations set forth in Section 4.6 for each Independent Product and Post-Termination Product, including any Post-Termination Product that was formally a Collaboration Product.

  
 2.28 Section 15.6.3(d) shall only apply to Post-Termination
Products. 
  
 2.29 Section 15.6.4 shall be
amended to read in its entirety as follows: 
  
 “15.6.4
Survival. Articles 1, 5, 7, 9, 11, 12, 13, 16, 17, 18, 19, 20, 21 and 22 and Sections 4.2(a), 4.3, 4.4.2, 4.5, 4.6, 6.1, 6.3, 6.4, 6.6, 7.6,8.3, 15.6 and 15.7 of this Agreement shall survive expiration or termination of this Agreement for any
reason.” 
  
 2.30 The attention line for the notice
provision to GCOR in Section 22.1 shall be revised to read: “Sr. Vice President, Health Care”. 
  
 [***] Confidential treatment requested. 
  

 -15- 

 3. Miscellaneous. 
  
 3.1 Continuing Effect. This Amendment shall be effective for all purposes as of the Effective Date. Except as
otherwise expressly modified by this Amendment, the Agreement shall remain in full force and effect in accordance with its terms. 
  
 3.2 Governing Laws. This Amendment shall be governed by, interpreted and construed in accordance with the laws of the State of Delaware, without
regard to conflicts of law principles. 
  
 3.3
Counterparts. This Amendment may be executed in counterparts, each of which shall be deemed to be an original and together shall be deemed to be one and the same document. 
  
 (Signature page follows) 
  

 -16- 

 IN WITNESS WHEREOF, the parties have caused this Amendment to be executed by their respective duly
authorized officers as of the Amendment Date. 
  

	 SEATTLE GENETICS, INC.

		
	 By:
	 	 /s/ Clay B. Siegall

	 	 	 (Signature)

		
	 Name:
	 	 Clay B. Siegall, Ph.D.

		
	 Title:
	 	 President and Chief Executive Officer

	
	 GENENCOR INTERNATIONAL, INC.

		
	 By:
	 	 /s/ Mark A. Goldsmith

	 	 	 (Signature)

		
	 Name:
	 	 Mark A. Goldsmith, M.D., Ph.D.

		
	 Title:
	 	 Senior Vice President, Health CareSeverance and Release Agreement with Amy P. Sing dated August 7, 2003

 Exhibit 10.2 
  
 SEVERANCE AND RELEASE AGREEMENT 
  
 This Severance and Release Agreement (“Agreement”) is made by and between Seattle Genetics, Inc., a
Delaware corporation (the “Company”), and Amy P. Sing, M.D. (“Employee”). 
  
 WHEREAS, Employee has been employed by the Company; 
  
 WHEREAS, the Company and Employee have mutually agreed to terminate Employee’s employment relationship and to release each other from any claims
arising from or related to the employment relationship; 
  
 NOW,
THEREFORE, in consideration of the mutual promises made herein, the receipt and sufficiency of which are hereby acknowledged, the Company and Employee hereby agree as follows: 
  
 1. Non-Admission of Liability. This Agreement shall not be construed as an admission by the Company that it acted
wrongfully with respect to Employee or as an admission by Employee of any wrongdoing. 
  
 2. Termination of Employment. 
  
 (a) The effective date of the termination of Employee’s employment with the Company will be August 29, 2003 (the “Termination Date”). On or before the Termination Date, the Company shall pay to Employee all salary,
wages, accrued and unused vacation through the Termination Date and any and all other benefits due to Employee with respect to her employment. 
  
 (b) Commencing July 1, 2003, Employee will not be required to be in attendance at the Company’s offices. Instead, Employee will make herself
reasonably available for consultation by the Company on an as-needed basis for up to fifteen (15) hours per week until the Termination Date, including without limitation checking and responding to her voicemail and email at least once per
workday. 
  
 3. Consideration. 
  
 (a) Severance and Benefits. In consideration for the release of
claims set forth below and other obligations under this Agreement, and provided that Employee returns this fully executed Agreement on or before August 6, 2003 and does not revoke it during the Revocation Period described in Section 8 below, the
Company agrees to provide to Employee the following severance benefits: (a) on the Termination Date, payment of a lump sum gross severance amount of Ninety-Eight Thousand Thirteen Dollars and Twenty-Four Cents ($98,013.24), subject to withholding of
applicable taxes, which is equal to six (6) months of Employee’s regular base salary; (b) waiver of the Company’s repurchase right with respect to Employee’s stock options that were early exercised as described in Section 4(b) below;
and (c) payment of Employee’s COBRA health insurance premiums from the Termination Date through February 29, 2004 as set forth in Section 5 below. 

 (b) Loan Repayment. During 2000, the Company provided Employee with two loans in connection with
Employee’s early exercise of certain stock options. According to the terms of the notes, these loans become due and payable in full on the Termination Date. Employee acknowledges that she is required to repay the full amount of principal plus
interest of these loans in accordance with their terms. 
  
 4.
Equity Ownership. 
  
 (a) Current Ownership. During
the course of Employee’s employment, the Company has granted to Employee options to purchase a total of 260,000 shares of the Company’s common stock under the terms of the Company’s Amended and Restated 1998 Stock Option Plan (the
“Plan”). Employee has exercised options to purchase 200,000 shares, of which 13,438 shares remain subject to a repurchase right at cost on behalf of the Company as of the Termination Date. In addition, Employee holds outstanding
options to purchase 60,000 shares, of which 16,666 shares are vested and exercisable as of the Termination Date. 
  
 (b) Stock Ownership. The Company and Employee agree that, as of the Termination Date, Employee shall be entitled to retain ownership of all 200,000
shares already exercised pursuant to Employee’s options, and the Company waives its right to repurchase the 13,438 shares still subject to the Company’s repurchase right. Employee shall also retain ownership of all shares of the
Company’s common stock Employee received through the Company’s Employee Stock Purchase Plan and the 1998 Stock Bonus Plan. 
  
 (c) Stock Options. Employee currently has the following outstanding stock options: 
  

	 Grant Date

	  	Exercise Price

	  	Total Shares Subject
to the Option

	  	Vested Shares as of
Termination Date

				
	 October 26, 2001
	  	$	3.9985	  	20,000	  	9,166
				
	 February 1, 2002
	  	$	6.34	  	15,000	  	5,625
				
	 April 26, 2002
	  	$	6.00	  	15,000	  	5,000
				
	 January 31, 2003
	  	$	3.30	  	10,000	  	0

  
 The Company agrees to
accelerate the vesting of Employee’s stock options granted on October 26, 2001 and January 31, 2003 such that they shall be fully vested and exercisable for an aggregate of 30,000 shares as of the Termination Date. Employee’s other two
options granted on February 1, 2002 and April 26, 2002 shall not be accelerated, but shall remain vested and exercisable for an aggregate of 10,625 shares as of the Termination Date as indicated in the table above. Employee shall have the right, for
the period of time specified in Employee’s stock option agreements and the Plan, to exercise any or all of the 40,625 shares subject to her outstanding options that are vested and exercisable as of the Termination Date after taking into account
the acceleration of vesting provided herein. 
  

 -2- 

 (d) Employee acknowledges that, as to any option shares: (i) that are not vested and exercisable as of
the Termination Date after giving effect to the acceleration of vesting provided pursuant to Section 4(c) above, or (ii) that are not exercised in accordance with Employee’s stock option agreements and the Plan, the options shall be void and
the vested shares of the Company’s common stock subject to the options shall be forfeited. Except as set forth in this Section 4, Employee acknowledges that as of the Termination Date, Employee has no right, title or interest in or to any
additional shares of the Company’s capital stock under the agreements referenced herein or any other document, instrument or arrangement with the Company. 
  

5. Benefits. Following the Termination Date, Employee and/or her covered dependents may elect COBRA medical, dental and vision plan continuation
coverage for the time period and under such conditions as are provided by COBRA. As set forth in Section 3(a), the Company will pay Employee’s COBRA health insurance premiums through February 29, 2004. 
  
 6. Property Return. Employee agrees to immediately review all personal
items and return to the Company all Company-owned property in Employee’s possession, such as all keys to Company buildings or property, all Company-owned equipment, all Company software, documents and papers (such as reports, presentations,
notebooks, and files), all Company credit cards, and all other Company property. Employee agrees to destroy personal copies of such property and shall not use or transfer any Company property to others. 
  
 7. Release of Claims. In exchange for the consideration under this
Agreement which Employee would not otherwise be entitled to receive, Employee and her successors and assigns thereby fully and forever release and discharge the Company, any of its subsidiary or related companies, any Company-sponsored employee
benefit plan in which Employee participates and any of their officers, directors, trustees, stockholders, agents, employees, investors, stockholders, administrators, and their successors and assigns from any claim, duty, obligation or cause of
action relating to any matters of any kind, whether known or unknown, suspected or unsuspected, that Employee may possess arising from any omissions, acts or facts that have occurred up until and including the date of this Agreement, including,
without limitation: 
  
 (a) any and all claims relating to or
arising from Employee’s employment relationship with the Company and termination of that relationship; 
  
 (b) any and all claims relating to, or arising from, Employee’s right to purchase, or actual purchase of shares of stock of the Company; 

 
 (c) any and all claims for personal injury, wrongful discharge of
employment, breach of contract (both express and implied), breach of a covenant of good faith and fair dealing (both express and implied), negligent or intentional infliction of emotional distress, negligent or intentional misrepresentation,
negligent or intentional interference with contract or prospective economic advantage and defamation; 
  

 -3- 

 (d) any and all claims for violation of any federal, state or local statute, including, but not limited
to the Title VII of the Civil Rights Act of 1964, the Age Discrimination in Employment Act, the Older Workers’ Benefits Protection Act, the Employee Retirement and Income Retirement Security Act, the Workers Retraining and Notification Act, and
the Rev. Code of Washington Sections 49.45.010 et. seq. and 49.60.010 et. seq.; 
  
 (e) any and all claims arising out of any other state, federal or local laws and regulations relating to employment or employment discrimination; and 
  
 (f) any and all claims for attorney’s fees and costs. 
  
 Employee and the Company agree that the release set forth in this Section 7 shall be and shall remain in effect as a complete general
release as to the matters released. This release does not extend to any obligations incurred under this Agreement or to any rights or claims that may arise after the date of this Agreement. 
  
 8. Acknowledgement of Wavier of Claims under ADEA. Employee
acknowledges that she is waiving and releasing any rights she may have under the Age Discrimination in Employment Act of 1967 (“ADEA”) and that this waiver and release is knowing and voluntary. Employee and the Company agree that
this waiver and release does not apply to any rights or claims that may arise under the ADEA after the Effective Date. Employee acknowledges that the consideration given for this Agreement is in addition to anything of value to which Employee was
already entitled. Employee further acknowledges that she has been advised by this writing that: (a) she should consult with an attorney prior to executing this Agreement; (b) she has twenty-one (21) days in which to consider this
Agreement; (c) she has seven (7) days following executing this Agreement to revoke this Agreement (the “Revocation Period”); and (d) this Agreement shall not be effective until the Revocation Period has expired. Any revocation
should be in writing and delivered to Kirsten Smith at the Company by close of business on the seventh (7th) day from the
date that Employee signs this Agreement. Unless revoked in accordance with this paragraph, the Agreement will become final and irrevocable on the eighth (8th) day following execution of this Agreement. 
  
 9. Confidentiality. Because the Company does not offer severance benefits as contemplated by this Agreement to all
terminating employees, it is important to the Company that both the fact of the severance package as well as the amount of the package remains confidential to the extent possible, subject to the Company’s compliance with disclosure requirements
under securities laws and regulations. Employee therefore agrees to maintain in confidence the existence of this Agreement, the contents and terms of this Agreement, and the consideration for this Agreement (hereinafter collectively referred to as
“Settlement Information”). Employee agrees not to disclose any Settlement Information to third parties, and agrees that there will be no publicity, directly or indirectly, concerning any Settlement Information except to her spouse,
attorney, accountant or other similar advisor and shall direct those individuals to maintain the confidentiality of this Agreement. 
  
 10. No Other Filings. Employee represents that she has not filed any claim that was released in this Agreement against the Company or its
releasees, and that she will not do so at any time in the future; however this will not limit Employee from filing a claim to enforce the terms of this Agreement. 
  

 -4- 

 11. Nondisclosure of Confidential and Proprietary Information. 
  
 (a) Employee shall continue to maintain the confidentiality of all
confidential and proprietary information of the Company as provided by the Proprietary Information and Inventions Agreement previously entered into between the Company and Employee, which agreement shall remain in effect pursuant to its terms.
Employee agrees that at all times hereafter, Employee shall not intentionally divulge, furnish or make available to any party any of the trade secrets, patents, patent applications, price decisions or determinations, inventions, customers,
proprietary information or other intellectual property rights of the Company, until after such time as such information has become publicly known otherwise than by act of collusion of Employee. Employee warrants that she has returned all the
Company’s property and confidential and proprietary information in her possession. 
  
 (b) Employee further acknowledges that during the course of her employment, Employee has acquired highly personal and confidential information about the Company’s directors, stockholders, officers, agents,
representatives and employees, past and present, their families, friends, business associates, investments, financial affairs, and business interests. Employee agrees that she will respect the confidences of these individuals and will not at any
time directly or indirectly divulge or disclose for any purpose whatsoever, or use for Employee’s own benefit, any confidential information that has been obtained by or disclosed to Employee as a result of her employment with the Company.

  
 12. Nondisparagement; Unemployment Benefits.

  
 (a) Employee agrees not to disparage the Company, its
affiliates, employees, agents, directors, officers, stockholders, representatives or employees, past or present. A disparaging statement is any oral or written comment, which in the mind of a reasonable person would tend to diminish the reputation,
business condition, integrity, competence or good character of another. Moreover, Employee will not speak about the Company with any banker, analyst, broker or existing or potential business partner of the Company without the prior written approval
of the Company’s Chief Executive Officer. The parties acknowledge and agree that any breach of this Section 12(a) is a material breach of this Agreement. 
  

(b) The Company agrees to provide an employment reference for Employee. Employee agrees to direct all prospective employers to contact either Clay B.
Siegall or H. Perry Fell. Drs. Siegall and Fell agree to provide truthful and positive information about Employee when responding to requests for employment references. 
  
 (c) The Company agrees not to dispute Employee’s receipt of unemployment benefits after the Termination Date.

  
 13. Breach of this Agreement. Employee acknowledges
that upon her breach of Section 11 or Section 12 of this Agreement, the Company would sustain irreparable harm from such breach, and, therefore, Employee agrees that in addition to any other remedies that the Company may have for any breach of this
Agreement or otherwise, the Company shall be entitled to obtain equitable relief, including specific performance and injunctions, restraining Employee from committing or continuing any such violation of this Agreement. 
  

 -5- 

 14. No Representations. Each Party represents that it has carefully read and understands the scope
and effect of the provisions of this Agreement. Neither Party has relied upon any representations or statements made by the other Party which are not specifically set forth in this Agreement. 
  
 15. Severability. In the event that any provision hereof becomes or is
declared by a court of competent jurisdiction to be illegal, unenforceable or void, said provision may be modified by the court to the extent necessary to render it enforceable and the remainder of this Agreement shall continue in full force and
effect. 
  
 16. Effective Date. This Agreement is effective
after it has been signed by both Parties and when eight (8) days have passed since Employee has signed the Agreement (the “Effective Date”), unless revoked by Employee within seven (7) days after the date the Agreement was signed by
Employee. 
  
 17. Entire Agreement. This Agreement
represents the entire agreement and understanding between the Company and Employee concerning Employee’s separation from the Company and supersedes and replaces any and all prior agreements and understandings concerning Employee’s
relationship with the Company and her compensation by the Company other than the Stock Option Agreements and Plan described in Section 4 and the Proprietary Information and Inventions Agreement described in Section 11. 
  
 18. No Oral Modification. This Agreement may only be amended in
writing signed by Employee and the Company. 
  
 19. Governing
Law. This Agreement shall be governed by the laws of the State of Washington. 
  
 20. Counterparts. This Agreement may be executed in counterparts, and each counterpart shall have the same force and effect as an original and shall constitute an effective, binding agreement on the part of
each of the undersigned. 
  
 21. Assignment. This Agreement
may not be assigned by Employee or the Company without the prior written consent of the other Party. Notwithstanding the foregoing, this Agreement may be assigned by the Company to a corporation controlling, controlled by or under common control
with the Company without the consent of Employee. 
  
 22.
Authority. The Company represents and warrants that the undersigned has the authority to act on behalf of the Company and to bind the Company and all who may claim through it to the terms and conditions of this Agreement. Employee represents
and warrants that she has the capacity to act on her own behalf and on behalf of all who might claim to be bound by the terms and conditions of this Agreement. Each Party warrants and represents that there are no liens or claims of lien or
assignments in law or equity or otherwise of or against any of the claims or causes of action released herein. 
  

 -6- 

 23. Voluntary Execution of Agreement. This Agreement is executed voluntarily and without any
duress or undue influence on the part or behalf of the parties hereto, with the full intent of releasing all claims. The parties acknowledge that: 
  

	 	(a)	 	They have read this Agreement; 

  

	 	(b)	 	They have been represented in the preparation, negotiation, and execution of this Agreement by legal counsel of their own choice or that they have voluntarily declined to seek such
counsel; 

  

	 	(c)	 	They understand the terms and consequences of this Agreement and of the releases it contains, and 

  

	 	(d)	 	They are fully aware of the legal and binding effect of this Agreement. 

  
 Employee acknowledges and agrees that she has been given at least twenty-one (21) days to decide whether to sign this Agreement, and has signed it only
after full reflection and analysis. Employee further acknowledges that Employee has been encouraged to obtain an attorney’s independent counsel and advice, and that Employee has read and understands the complete Agreement. By signing this
Agreement prior to the expiration of the twenty-one (21) day period set forth in Section 8 herein, Employee acknowledges and agrees that she had adequate time and opportunity to fully consider her rights and this release of them. 
  
 [Signature page follows] 
  

 -7- 

 IN WITNESS WHEREOF, the Parties have executed this Severance and Release Agreement on the respective
dates set forth below. 
  

	COMPANY:	 	 	  	EMPLOYEE:
			
	SEATTLE GENETICS, INC.	 	 	  	AMY P. SING, M.D.
				
	 By:
	 	 /s/ Clay B. Siegall

	 	 	  	 /s/ Amy P. Sing

	 	 	 	 	 	  	(Signature)
			
	 Name: Clay B. Siegall
	 	 	  	 Amy P. Sing, M.D.

	 	 	 	  	(Print Name)
			
	 Title: President & CEO
	 	 	  	 
			
	 Date: August 7, 2003
	 	 	  	 Date: July 30, 2003

  

 -8-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00058-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00058-of-00352.parquet"}]]